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Abstract
TB, caused by Mycobacterium tuberculosis (MTB), is one of the major global infectious diseases. For the pandemic
control, early diagnosis with sensitive and specific methods is fundamental. With the advent of bioinformatics’
tools, the identification of several proteins involved in the pathogenesis of TB (TB) has been possible. In the
present work, the MTB genome was explored to look for molecules with possible antigenic properties for their
evaluation as part of new generation diagnostic kits based on the release of cytokines. Seven proteins from the
MTB proteome and some of their combinations suited the computational test and the results suggested their
potential use for the diagnosis of infection in the following population groups: Cuba, Mexico, Malaysia and sub-
Saharan Africa. Our predictions were performed using public bioinformatics tools plus three computer programs,
developed by our group, to facilitate information retrieval and processing.
Introduction
MTB is the causative agent of TB. The only TB vaccine
available, Bacille Calmette-Guérin (BCG) has been admi-
nistered to more than one billion people and is routinely
given to infants (not infected with HIV) worldwide.
Although BCG provides a considerable degree of protec-
tion against pediatric TB, it does not protect people with
HIV and it is unreliable against adult forms of pulmonary
TB [1].
The association of TB with HIV/AIDS has dramatically
increased the incidence of this disease. One-third of the
world’s population is infected with MTB and approxi-
mately 9 million people develop the active form of the
disease every year with nearly 2 million deaths. It has
been estimated that if no improvements in TB control
are made, about 10 million people will die from TB by
2015 [2].
Early diagnosis is fundamental to prevent TB transmis-
sion and to minimize the risk of disease progression. The
majority of patients are detected at an advanced stage of
the disease, after having transmitted it to their closest
contacts [3]. However, the development of new diagnostics
poses great challenges to the scientific community, since
our understanding of many of the underlying biological
processes remains incomplete, and suitable biomarkers are
yet to be identified. The identification of bacterial and/or
host molecules that differentiate between people with
active TB, those with latent infection and individuals not
affected by TB are of priority to drive critical innovation,
including the development of diagnostic tests with greater
sensitivity and specificity [2].
New diagnostic methods include those based on the
measurement of cytokine concentration such as inter-
feron-gamma, released by the stimulation of blood lym-
phocytes [3]. The improvement of this type of diagnostic
tests depends on the availability of antigens that provide
greater sensitivity and ensure a specific response.
In the present work, using in silico methodologies, a
group of MTB proteins were identified with the potential
to induce the production of cytokines by the lymphocytes
of MTB infected individuals without the production of
cross reactive responses against BCG, Mycobacterium
bovis (Mb) or environmental mycobacteria. The selected
bacterial molecules were evaluated in silico to determine
its biological function, sub-cellular location and its
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expression in vivo. Moreover, epitopes associated with
the selected antigens were identified and their degree of




The whole genomic sequences of MTB H37Rv [4], Mb
AF2122/97 [5] and the regions of differences found by
Behr between MTB H37Rv, Mb and BCG [6] were used.
Informatics and computational resources
Comparisons of sequences of MTB H37Rv against whole
sequenced genomes of other MTB strains, Mb AF2122/97,
M. smegmatis (Ms) and M. avium (Ma) were made with
local sequence alignment tools: tfastax from FASTA 36.3.4
[7,8] and tblastn from BLAST 2.2.25+ [9].
Subcellular localization was predicted using Tbpred,
SignalP and PSort servers [10-12]
HLAPred server was used to carry out the prediction
of T cell epitopes corresponding to the selected proteins
of MTB H37Rv, and the “Population Coverage Calcula-
tion” server [13] allowed the estimation of the theoreti-
cal population coverage of these epitopes in several
geographic areas of interest.
The MTB antigens expressed in vivo in different spe-
cies was determined by bibliographic search using goo-
gle scholar, PubMed and PubMed Central.
Our bioinformatics approach was based on the use of
already available bioinformatics resources combined
with three auxiliary computational programs: NCBIRea-
der, EBIFASTAProcessor and EpiFormat developed by
our group (Calero R et al, unpublished results).
Results and discussion
Behr and colleagues identified 16 regions of differences
(RD1-RD16) between MTB H37Rv, Mb and BCG which
encompasses a total of 129 open reading frames (ORF);
we refer to them as “Behr’s regions”. Eleven of these
regions are absent from Mb; the other five regions are
present in Mb but absent from BCG.
We choose as starting point 100 ORFs that comprise
twelve of the Behr´s regions. Four regions were discarded
(RD2, RD8, RD14 and RD16) because they are present in
some strains of BCG, in order to avoid cross reactivity
with any BCG strain.
When comparing the genome sequences of Mb
AF2122/97 with the 100 ORFs of MTB H37Rv, eleven
ORFs had no significant alignments with Mb.
These 11 ORFs were compared with three sequenced
strains of MTB (MTB F11, MTB KZN 1435 and MTB
CDC1551). With the exception of one ORF (Rv3428c), all
of them exhibited significant alignments and identities
above 98% with each of the three strains of MTB; the ORF
Rv3428c had only a single significant alignment with MTB
F11. None of the 10 remaining ORFs gave significant
alignments with the genome of Ms, but three ORFs
(Rv2657c, Rv2348c and Rv1514c) gave significant align-
ment with Ma and therefore were discarded. The seven
finally selected ORFs are shown in Table 1.
From these seven ORFs a collection of T cell epitopes
was identified, establishing the position in which they are
located in the amino acid sequence of the protein, the
group of alleles that has affinity for each of them, and the
corresponding degree of affinity (prediction score). It was
also possible to identify promiscuous epitopes and their
corresponding alleles. This knowledge, together with the
full sequence of each epitope, served to theoretically esti-
mate the potential population coverage of the selected
antigens. In turn, the knowledge of the population cover-
age served to calculate an a priori estimate of the potenti-
ality of the antigens (or their combinations), to be used in
different geographical regions. Coverage of combination of
two or three of the selected protein sequence was also pre-
dicted. Focusing on the Cuban population, the information
contained in previous works [14-17] was useful to create
an updated version of the allele database contained in the
Population Coverage Calculation Server.
The theoretical predictions of the coverage (HLA Class
I & Class II) are summarized in Figure 1. Four proteins
and three of their combinations offer coverage of more
than 80% for all the tested populations.
Table 1 Selected proteins
ORF Description Region Subcellular location In vivo expression
Human Mice Guinea Pig
Rv2658c Prophage protein RD13 Cytoplasmic
Rv2655c Prophage protein phiRv2 RD13 Cytoplasmic
Rv2653c Prophage protein phiRv2 RD13 Cytoplasmic
Rv2645 Hypothetical protein RD13 Cytoplasmic X X
Rv1509 Hypothetical protein RD6 Membrane
Rv1507c Hypothetical protein RD6 Cytoplasmic
Rv1508c Hypothetical protein RD6 Membrane X X X
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The bioinformatics strategy proposed and used here
has rendered positive results: several molecules that have
promising antigenic properties to be used in the develop-
ment of diagnostic tests for TB, have been identified. Our
selection procedure theoretically guarantees that these
antigens have the potential to offer an adequate degree of
specificity to recognize the MTB infection, minimizing
the likelihood of false positive, in conditions that are typi-
cal in the geographical areas of high incidence of TB: vac-
cination with BCG, Mb infection or infections with
environmental mycobacteria [18,19]. These predictive
results should be confirmed in future human studies car-
ried out in different populations.
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